Apixaban: an emerging oral factor Xa inhibitor.

Journal of Thrombosis and Thrombolysis
Christopher Roser-Jones, Richard C Becker

Abstract

Apixaban, an oral direct factor Xa inhibitor, is currently in late stage clinical development for the prevention and treatment of thromboembolic diseases. In comparison with current treatment standards for venous thromboembolism (VTE) prophylaxis, apixaban has shown decreased rates of clinically significant bleeding with mixed results in terms of non-inferiority for VTE events. Secondary treatment of VTE with apixaban is currently in phase III clinical study after earlier trials showed comparable safety and efficacy outcomes. The APPRAISE-1 trial, a phase II investigation of apixaban versus placebo following acute coronary syndrome showed a higher risk of clinically significant bleeding in addition to a trend toward decreased ischemic events. A large, international phase III clinical study (APPRAISE-2) of apixaban following acute coronary syndrome is currently underway. Large, phase III studies testing apixaban for the prevention of vascular events in subjects with non-valvular atrial fibrillation are also ongoing.

References

Dec 20, 2007·Journal of Thrombosis and Haemostasis : JTH·B I ErikssonUNKNOWN Fixit Study Group
Jun 11, 2008·Journal of Thrombosis and Haemostasis : JTH·UNKNOWN Botticelli Investigators, Writing CommitteA Segers
Oct 4, 2008·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Nirmala RaghavanDonglu Zhang
Apr 8, 2009·Thrombosis and Haemostasis·Xiaosui JiangPancras C Wong
Aug 7, 2009·The New England Journal of Medicine·Michael Rud LassenRonald J Portman
Apr 5, 2011·European Journal of Drug Metabolism and Pharmacokinetics·Kan HeScott J Grossman

❮ Previous
Next ❯

Citations

Feb 24, 2010·Journal des maladies vasculaires·A Godier, C-M Samama
Nov 9, 2010·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·David Stegner, Bernhard Nieswandt
May 15, 2013·Expert Opinion on Drug Safety·Flavio de Souza BritoJohn H Alexander
Jan 17, 2012·The American Journal of the Medical Sciences·Harsh GolwalaMazen S Abu-Fadel
Aug 7, 2012·Neurología : publicación oficial de la Sociedad Española de Neurología·G Zapata WainbergJ Vivancos Mora
Sep 29, 2011·Pharmacotherapy·Estella M DavisJennifer A Campbell
Jul 22, 2010·Cardiovascular Therapeutics·Luke R E Bereznicki, Gregory M Peterson
Sep 18, 2016·Hematology/oncology Clinics of North America·Nicoletta Riva, Walter Ageno
May 12, 2011·International Journal of Stroke : Official Journal of the International Stroke Society·Luca MasottiDomenico Prisco
Jan 15, 2014·Hospital Pharmacy·Dennis J CadaDanial E Baker
Mar 13, 2012·Clinical Medicine Insights. Cardiology·Yousif Ahmad, Gregory Y H Lip
May 21, 2014·Cardiovascular Drugs and Therapy·A JalotaJ Halperin
Feb 15, 2011·American Journal of Therapeutics·Suraj ChandrasekarRohit Arora
Jul 27, 2021·Ophthalmic Surgery, Lasers & Imaging Retina·Matthew R StarrAllen Chiang
Nov 30, 2021·Journal of the American Chemical Society·Wowa StroekMartin Albrecht

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atrial Filbrillation

Atrial fibrillation refers to the abnormal heart rhythm characterized by rapid and irregular beating of the atria. Here is the latest research.

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.